| Human immunodeficiency virus I infection

Fuzeon vs Rukobia

Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.
Deep comparison between: Fuzeon vs Rukobia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsRukobia has a higher rate of injection site reactions vs Fuzeon based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rukobia but not Fuzeon, including UnitedHealthcare
Sign up to reveal the full AI analysis
Fuzeon
Rukobia
At A Glance
SC injection
Twice daily
HIV-1 fusion inhibitor
Oral
Twice daily
HIV-1 attachment inhibitor
Indications
  • Human immunodeficiency virus I infection
  • Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (Adults) 90 mg (1 mL) SC twice daily injected into the upper arm, anterior thigh, or abdomen.
Human immunodeficiency virus I infection (Pediatric, >=11 kg) 2 mg/kg SC twice daily up to a maximum of 90 mg twice daily injected into the upper arm, anterior thigh, or abdomen; adjust dose with weight changes.
Human immunodeficiency virus I infection 600 mg orally twice daily with or without food; swallow tablets whole, do not chew, crush, or split.
Contraindications
  • Known hypersensitivity to enfuvirtide or any excipient of FUZEON
  • Previous hypersensitivity to fostemsavir or any component of RUKOBIA
  • Coadministration with strong CYP3A inducers, including enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (Hypericum perforatum)
Adverse Reactions
Most common Local injection site reactions (pain/discomfort, induration, erythema, nodules/cysts, pruritus, ecchymosis), diarrhea, nausea, fatigue, weight decreased, sinusitis, abdominal pain, cough, herpes simplex, appetite decreased, pancreatitis, pneumonia, myalgia
Serious Pneumonia, hypersensitivity reactions, renal failure, Guillain-Barre syndrome, thrombocytopenia, neutropenia, sepsis, toxic hepatitis, unstable angina pectoris
Postmarketing Cutaneous amyloidosis at the injection site
Most common (>=2%) Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance, immune reconstitution inflammatory syndrome, somnolence, vomiting
Serious Immune reconstitution inflammatory syndrome, QTc prolongation, hepatic transaminase elevations in patients with hepatitis B or C virus co-infection
Pharmacology
Enfuvirtide is an HIV-1 fusion inhibitor that binds to the first heptad-repeat (HR1) domain of the gp41 subunit of the viral envelope glycoprotein, preventing the conformational changes required for fusion of viral and cellular membranes and thereby blocking HIV-1 entry into CD4+ cells.
HIV-1 attachment inhibitor; fostemsavir is a prodrug hydrolyzed to temsavir, which binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein and selectively inhibits the interaction between the virus and cellular CD4 receptors, preventing viral attachment and subsequent entry into host cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fuzeon
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (0/12) · Qty limit (1/12)
View full coverage details ›
Rukobia
  • Covered on 5 commercial plans
  • PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Fuzeon
  • Covered on 4 commercial plans
  • PA (4/8) · Step Therapy (2/8) · Qty limit (2/8)
View full coverage details ›
Rukobia
  • Covered on 4 commercial plans
  • PA (4/8) · Step Therapy (0/8) · Qty limit (2/8)
View full coverage details ›
Humana
Fuzeon
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
View full coverage details ›
Rukobia
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
FuzeonView full Fuzeon profile
RukobiaView full Rukobia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.